recombinant human il-28b/ifn-lambda 3 protein (Bio-Techne corporation)
94
Structured Review
Bio-Techne corporation
recombinant human il-28b/ifn-lambda 3 protein
Recombinant Human Il 28b/Ifn Lambda 3 Protein, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 73 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/5259-IL/Recombinant+Human+IL-28B%2FIFN-lambda+3+Protein/custom%405259-il%4040037352
Average 94 stars, based on 73 article reviews
Recombinant Human Il 28b/Ifn Lambda 3 Protein, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 73 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/5259-IL/Recombinant+Human+IL-28B%2FIFN-lambda+3+Protein/custom%405259-il%4040037352
Average 94 stars, based on 73 article reviews
recombinant human il-28b/ifn-lambda 3 protein - by Bioz Stars,
2026-11
94/100 stars
Images
Related Articles
Clinical Proteomics:Article Title: Increased prevalence of autoantibodies neutralizing IFNλ2/3 in young individuals with cystic fibrosis Article Snippet: n patient plasmas was performed with a multiplexed, bead-based assay using 1:100 diluted plasma samples, similar to described ( 5 ). Protein targets were: IFNλ1 (NBP2-34996; Novusbio), IFNλ2 (8417-IL; Activity Assay:Article Title: Increased prevalence of autoantibodies neutralizing IFNλ2/3 in young individuals with cystic fibrosis Article Snippet: n patient plasmas was performed with a multiplexed, bead-based assay using 1:100 diluted plasma samples, similar to described ( 5 ). Protein targets were: IFNλ1 (NBP2-34996; Novusbio), IFNλ2 (8417-IL; Bead-based Assay:Article Title: Increased prevalence of autoantibodies neutralizing IFNλ2/3 in young individuals with cystic fibrosis Article Snippet: n patient plasmas was performed with a multiplexed, bead-based assay using 1:100 diluted plasma samples, similar to described ( 5 ). Protein targets were: IFNλ1 (NBP2-34996; Novusbio), IFNλ2 (8417-IL; |